AptaBio Therapeutics Inc (293780) — Financial Flexibility Index
AptaBio Therapeutics Inc (293780) has a Financial Flexibility Index of -0.12x as of September 2025. Free cash flow of ₩-2.71 Billion (operating CF ₩-2.73 Billion minus capex ₩16.17 Million) represents 0% of total liabilities (₩22.51 Billion). Check 293780 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
AptaBio Therapeutics Inc Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for AptaBio Therapeutics Inc across 8 annual periods. For the full cash flow conversion analysis, see 293780 operating cash flow.
Annual Financial Flexibility Index for AptaBio Therapeutics Inc (2017–2024)
Year-by-year free cash flow to debt coverage for AptaBio Therapeutics Inc. Explore debt repayment capacity of AptaBio Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.51x | ₩-11.92 Billion | ₩-12.16 Billion | ₩23.24 Billion | ▼ -14.7% |
| 2023 | -0.45x | ₩-13.93 Billion | ₩-14.10 Billion | ₩31.16 Billion | ▲ +71.1% |
| 2022 | -1.55x | ₩-5.79 Billion | ₩-6.83 Billion | ₩3.74 Billion | ▲ +42.5% |
| 2021 | -2.69x | ₩-8.74 Billion | ₩-8.90 Billion | ₩3.25 Billion | ▼ -337.5% |
| 2020 | -0.62x | ₩-2.09 Billion | ₩-3.79 Billion | ₩3.40 Billion | ▲ +57.0% |
| 2019 | -1.43x | ₩-3.22 Billion | ₩-6.00 Billion | ₩2.25 Billion | ▼ -67.7% |
| 2018 | -0.85x | ₩-1.72 Billion | ₩-1.75 Billion | ₩2.02 Billion | ▼ -1937.4% |
| 2017 | -0.04x | ₩-1.78 Billion | ₩-1.79 Billion | ₩42.54 Billion | — |